A recent unusually warm Sunday evening in Mumbai transcended its initial purpose as a mere social gathering, morphing into a strategic summit for India’s pharmaceutical leadership. In the opulent ballroom of a five-star hotel, over 1,500 luminaries—comprising industry titans, senior policymakers, leading academics, and ambitious entrepreneurs—convened ostensibly for a book launch. Yet, the event quickly evolved into an intensive discourse on the pivotal future trajectory of one of India’s most economically significant and globally impactful sectors. This convergence underscored a collective recognition that the Indian pharmaceutical industry stands at an inflection point, necessitating a profound strategic re-evaluation.
The catalyst for this extraordinary assembly was the unveiling of "Made in India," a meticulously researched biography of Lupin’s late founder, Desh Bandhu Gupta. Co-authored by TeamLease Services co-founder Manish Sabharwal and Mint columnist Sundeep Khanna, the book chronicles Gupta’s remarkable life story, which, in parallel, narrates the dramatic ascent of the Indian pharmaceutical industry itself. The narrative, forged through an astonishing 28 iterations over three years, mirrors the relentless persistence, ingenuity, and capacity for reinvention that characterized Gupta’s entrepreneurial journey and, by extension, the entire sector. It traces three interwoven sagas: the personal odyssey of Desh Bandhu Gupta, the organic growth of Lupin as a pharmaceutical giant, and the transformative emergence of India as the undisputed "pharmacy of the world." This journey saw a nation once heavily reliant on imported medicines develop the capability to supply affordable, high-quality drugs across the globe, fundamentally altering access to healthcare for millions.
The evening’s intellectual core was a high-powered panel discussion, featuring an unparalleled constellation of influence in Indian pharma. Present were Dilip Shanghvi, the visionary founder of Sun Pharma; G.V. Prasad, Co-Chairman of Dr. Reddy’s Laboratories; Yusuf Hamied, the revered patriarch of Cipla; Vinita Gupta, CEO of Lupin; and Professor M.M. Sharma, former director of the Institute of Chemical Technology (formerly UDCT), Mumbai. Moderated by Manish Sabharwal, Gupta’s son-in-law, the discussion navigated effortlessly between nostalgic reflections on past triumphs and a candid, often unvarnished, assessment of the formidable challenges and opportunities that lie ahead. The seamless transition of the evening’s proceedings, deftly compered by Gupta’s grandchildren, Noor Sabharwal and Krish Sharma, subtly reinforced the overarching theme: the imperative of being a "good ancestor" and forging a sustainable, innovative path for the next generation.
A broad, unequivocal consensus crystallized on stage: India’s formidable dominance in the small-molecule generics market, while a remarkable achievement that propelled the nation to global prominence, is reaching its natural limits. To sustain growth and enhance value, the industry must orchestrate a decisive pivot up the pharmaceutical value chain. This strategic shift demands significant investment and expertise in complex domains such as biologics, biosimilars, advanced peptides, sophisticated fermentation byproducts, and, ultimately, genuine novel drug discovery. G.V. Prasad articulated this urgency, stating, "If we don’t move up that curve, honing our skills in biologics, biosimilars, peptides, fermentation byproducts, and more efficient ways to synthesize, we can’t compete. That, I think, is important for us… then you have innovation, which is a different game." The global pharmaceutical market, projected to exceed $1.6 trillion by 2025, sees biologics as the fastest-growing segment, accounting for a significant and increasing share of new drug approvals and sales. India, currently holding a substantial share of the global generics market by volume (estimated at 20-25%), must now contend with escalating price pressures and increased competition in this segment, making the shift to higher-value products economically imperative.
The Indian government appears to be aligned with this strategic imperative. Recent Union budget announcements, which include substantial outlays aimed at fortifying India’s biopharmaceutical ecosystem, were met with widespread approval from an industry that has long advocated for policy support extending beyond generic manufacturing. These initiatives, such as Production Linked Incentive (PLI) schemes for pharmaceutical ingredients and dedicated funding for R&D infrastructure, signal a concerted effort to foster an environment conducive to complex manufacturing and innovation. However, Yusuf Hamied offered a historical perspective, tracing the origins of Indian scientific research institutions like the Council of Scientific and Industrial Research (CSIR) and the Indian Council of Medical Research (ICMR) back to 1934. He emphasized that future research and product development, especially in novel areas, necessitate robust partnerships between the government, research laboratories, and academic institutions, envisioning joint projects as the most viable pathway.
Yet, Hamied was unsparingly candid about the inherent limitations of Indian companies attempting novel drug development in isolation. "Alone, an Indian company will not succeed in developing a new drug, although there will be exceptions. Even with an international partner, you could succeed," he remarked. This sentiment highlights the enormous capital expenditure, prolonged timelines (often 10-15 years), and high failure rates associated with new chemical entity (NCE) development, where costs can easily surpass $1 billion per successful drug. He also pointed to a persistent, often subtle, barrier: the "acceptability" challenge. Even within domestic markets, there remains a reluctance to fully trust Indian-made novel drugs unless they receive validation or endorsement from established global brands, reflecting deep-seated perceptions regarding quality, clinical rigor, and market credibility. This underscores a need not just for scientific prowess but also for robust global marketing and brand-building strategies.
The panel confronted uncomfortable truths regarding India’s innovation record. Professor M.M. Sharma was particularly critical, questioning both the scale and seriousness of India’s research and development (R&D) efforts. He lamented that India had squandered its early advantage in chemical manufacturing, subsequently ceding significant ground to China, which now dominates the global supply chain for Active Pharmaceutical Ingredients (APIs). India’s R&D spending, typically around 5-7% of pharmaceutical revenues, lags significantly behind global innovator companies, which often invest upwards of 15-20%. Sharma suggested that "formulation engineering," a relatively lower-risk and cost-effective research area focused on improving drug delivery, bioavailability, and patient compliance, could offer a more realistic and immediate path forward. Vinita Gupta echoed this, stating, "I think we have the possibility of really doing novel formulations, which is not as risky as the new chemical entity. We can double down on that." She advocated for a fundamental rebalancing of R&D priorities, proposing a gradual shift from the current 70% allocation to generics towards a 70% focus on innovation, a monumental undertaking requiring strategic foresight and sustained investment.
Dilip Shanghvi, whose Sun Pharma has strategically licensed innovative products, offered a pragmatic perspective on the elusive nature of innovation for Indian firms. "Our innovative products are licensed-in," he stated bluntly. "That, we thought, was the best way to understand the business of innovation. Part of the handicap is also that there are not many entrepreneurs or CEOs in India who have managed innovation." He reflected on talent acquisition choices made over the past two decades, suggesting that Indian companies may have underestimated the critical importance of highly specialized skills. Instead of actively recruiting individuals with deep, market-ready expertise, particularly from advanced global markets, firms often opted to train broadly qualified hires, creating a persistent gap in cutting-edge research and development capabilities.
The panel reached a unanimous conclusion: biopharmaceuticals represent both the most significant opportunity and the most substantial risk. Unlike small-molecule generics, biologics demand vastly longer development timelines, exponentially higher capital investment, and a profound tolerance for failure—characteristics that Indian companies have historically sought to mitigate. Shanghvi cautioned that not every large firm would, or indeed should, attempt this leap, advocating for diversified strategies tailored to individual company strengths and risk appetites. For Hamied, the answer lies in concerted, collective action. "At the root of it, the industry needs to come together to discuss how to make the leap towards innovation," he urged, proposing industry-wide deliberations on strategic sourcing and product development priorities.
Talent emerged as another recurring and critical theme. Shanghvi underscored that future success hinges on attracting and retaining highly specialized skills, necessitating a willingness to look beyond India’s borders for expertise. Manish Sabharwal succinctly captured this global imperative: "I think they all have to globalize. They have already globalized their customers. They sell into other countries. I think they have to globalize their supply chains, their R&D chains. That is the future. Globalize means do more in India, but also go to where talent is." This implies not only attracting foreign talent to India but also establishing R&D outposts in global innovation hubs.
The diverse and distinguished guest list at the Mumbai event underscored the profound significance of this moment. Industry veterans like D.S. Brar mingled with technology leaders such as Infosys co-founder Nandan Nilekani, signaling that Indian pharma’s next chapter will be intricately intertwined with evolving policy frameworks, disruptive technological advancements, and the strategic deployment of global capital. This cross-sectoral engagement reinforces the understanding that innovation in pharmaceuticals today is not a siloed scientific endeavor but a multidisciplinary challenge requiring collaboration across biotech, artificial intelligence, data analytics, and finance.
As the evening concluded, "Made in India" stood not merely as a biography of Desh Bandhu Gupta but as a reflective mirror held up to an industry he so instrumental in building—an industry now undeniably at a crossroads. The journey from adept reverse engineering to pioneering true innovation, the panel emphasized, will be considerably longer, riskier, and more uncertain than any path previously trodden. It demands a fundamental shift in mindset, investment priorities, and talent strategy. Yet, if the candid and rigorous discussions within that Mumbai ballroom were any indication, the necessary reckoning with this future has well and truly commenced, setting the stage for India to redefine its role in global healthcare for decades to come.
